TY - JOUR
T1 - Recent trends in molecular diagnostics of yeast infections
T2 - from PCR to NGS
AU - Gabaldón, Toni
AU - Buda De Cesare, Giuseppe
AU - Munro, Carol Anne
AU - OPATHY Consortium
N1 - This work was supported by European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No. H2020-MSCA-ITN-2014–642 095. EU OPATHY Innovative Training Network, Medical Research Council Centre for Medical Mycology and the University of Aberdeen (MR/N006364/1)
PY - 2019/9
Y1 - 2019/9
N2 - The incidence of opportunistic yeast infections in humans is increasing over the last years. These infections are difficult to treat and diagnose, in part due to the large number and broad diversity of species that can underlie the infection. In addition, resistance to one or several antifungal drugs in infecting strains is increasingly being reported, severely limiting therapeutic options and showcasing the need for rapid detection of the infecting agent and its drug susceptibility profiles. Current methods for species and resistance identification lack satisfactory sensitivity and specificity, and often require prior culturing of the infecting agent which delays diagnosis. Recently developed high-throughput technologies such as next generation sequencing or proteomics are opening completely new avenues for more sensitive, accurate, and fast diagnosis of yeast pathogens. These approaches are the focus of intensive research, but translation into the clinics requires overcoming important challenges. In this review, we provide an overview of existing and recently emerged approaches that can be used in the identification of yeast pathogens and their drug resistance profiles. Throughout the text we highlight the advantages and disadvantages of each methodology and discuss the most promising developments in their path from bench to bedside.
AB - The incidence of opportunistic yeast infections in humans is increasing over the last years. These infections are difficult to treat and diagnose, in part due to the large number and broad diversity of species that can underlie the infection. In addition, resistance to one or several antifungal drugs in infecting strains is increasingly being reported, severely limiting therapeutic options and showcasing the need for rapid detection of the infecting agent and its drug susceptibility profiles. Current methods for species and resistance identification lack satisfactory sensitivity and specificity, and often require prior culturing of the infecting agent which delays diagnosis. Recently developed high-throughput technologies such as next generation sequencing or proteomics are opening completely new avenues for more sensitive, accurate, and fast diagnosis of yeast pathogens. These approaches are the focus of intensive research, but translation into the clinics requires overcoming important challenges. In this review, we provide an overview of existing and recently emerged approaches that can be used in the identification of yeast pathogens and their drug resistance profiles. Throughout the text we highlight the advantages and disadvantages of each methodology and discuss the most promising developments in their path from bench to bedside.
KW - yeast pathogens
KW - diagnosis
KW - Candida
KW - candidemia
KW - sequencing
KW - proteomics
KW - INTERNAL TRANSCRIBED SPACER
KW - IN-SITU HYBRIDIZATION
KW - LASER-DESORPTION/IONIZATION-TIME
KW - CULTURE IDENTIFICATION PANEL
KW - ESCMID-ASTERISK GUIDELINE
KW - MALDI-TOF MS
KW - FLIGHT MASS-SPECTROMETRY
KW - DESORPTION IONIZATION-TIME
KW - CLINICAL-PRACTICE GUIDELINE
KW - BLOOD-STREAM INFECTIONS
UR - http://www.mendeley.com/research/recent-trends-molecular-diagnostics-yeast-infections-pcr-ngs
UR - http://www.scopus.com/inward/record.url?scp=85072058104&partnerID=8YFLogxK
U2 - 10.1093/femsre/fuz015
DO - 10.1093/femsre/fuz015
M3 - Review article
C2 - 31158289
VL - 43
SP - 517
EP - 547
JO - FEMS Microbiology Reviews
JF - FEMS Microbiology Reviews
SN - 0168-6445
IS - 5
ER -